Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma

NCT04879043 is registered in ClinicalTrials.gov with Heidelberg Pharma AG as lead sponsor.

NCT NCT04879043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04879043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma
Lead sponsor
Heidelberg Pharma AG
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 7, 2022
Completion date
September 30, 2028
Enrollment
78 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, plasma cell disorder